Bailite Tianheng (688506.SH) Innovative drug BL-ARC002 injection receives approval for clinical trials

LootboxPhobia · 2026-03-22T10:41:56+00:00

Zhitong Finance APP News - Bailitian Heng (688506.SH) announced that the company recently received a formal "Notice of Approval for Clinical Trial of Drug" issued and signed by the National Medical Products Administration (NMPA). The clinical trial of the company's independently developed innovative drug BL-ARC002 injection has been approved.According to the announcement, BL-ARC002 utilizes antibody-mediated precision targeted delivery technology and the potent tumor-killing capability of radionuclides. Compared with traditional radionuclide-coupled drugs, it demonstrates stronger target specificity, higher tumor enrichment, and is expected to exhibit better resistance to drug resistance.

LootboxPhobia

2026-03-22 10:41:56

Tongtong Finance APP News, Baili Tianheng (688506.SH) announced that the company recently received the “Drug Clinical Trial Approval Notice” officially issued by the National Medical Products Administration (NMPA), approving the clinical trial of its independently developed innovative drug BL-ARC002 injection.

The announcement states that BL-ARC002, through antibody-mediated precise targeted delivery technology and the powerful tumor-killing ability of radioactive nuclides, has stronger target specificity, higher tumor enrichment, and is expected to demonstrate better anti-drug resistance compared to traditional radioisotope conjugated drugs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes